Evaluation of Toxicity in Humans Generalizations Regarding Toxicologic Information Derived from Organized Clinical Trials
{"Image DocumentName": "Evaluation of Toxicity in Humans Generalizations Regarding Toxicologic Information Derived from Organized Clinical Trials", "Image ImageDescription": "For example, in the early phase I trials of fludarabine monophosphate, the acute delayed toxicity (DLT) in patients with solid tumors was reversible myelosuppression. The doses subsequently were escalated in patients with refractory forms of leukemia, and a delayed onset of serious neurologic toxicity was observed. Approximately 4 to 6 weeks after the administration of high doses of this agent, cortical blindness and coma developed in the patients. Therefore, myelosuppression was the DLT in the low dose range, and delayed neurologic toxicity was dose limiting in the high dose range.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}